|
|
Profile
|
Delegates :
Akiko Itai |
|
Incorporated :
March 16 , 1995 |
Paid in Capital :
145 Million yen |
Employees :
10 人 |
Address :
Hongo BN Bldg. 2-27-18 Hongo, Bunkyo-ku, TOKYO
〒113-0033
|
TEL/FAX :
+81-3-5689-4052 / +81-3-5689-4054 |
URL：
http://www.immd.co.jp/en/ |
Attachment :
|
Mission/Background :
IMMD was founded by Dr. Akiko Itai in 1995 focusing on its rational drug design technology. As a former professor of the Faculty of Pharmaceutical Sciences at the University of Tokyo, she is internationally recognized for her contributions to novel methodologies of rational drug design.
|
|
Technology & Business
|
IMMD is a drug discovery company with a leading-edge rational drug design technology. Its high capability greatly owes to the excellence of its proprietary software system. The technology enabled IMMD to identify dozens of drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses strategically, based on estimated docking mode to the target. The advantages of the method were proved by several successes of drug discovery from the collaboration research with partners as well as from its in-house programs.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
IMD-1041 (a prodrug of IKKb inhibitor IMD-0354)
|
Phase1/2
|
hyperinsulinemia
|
diabetis complications. lung fibrosis
|
IMD-2560 (a prodrug of IKKb inhibitor IMD-0560)
|
Phase1
|
RA, Osteoarthritis Potently inhibits of IL-6 production.
|
|
IMD-0354 (IKKb inhibitor)
|
Preclinical
|
Stroke , cancer
|
|
IMD-4482 (PAI-1 inhibitor)
|
Preclinical
|
Alzheimer’s disease, Cerebrovascular dementia
|
|
IMD-4852 (PAI-1 inhibitor)
|
Preclinical
|
Thrombosis (Thrombosis after surgery, DVT, DIC etc)
|
|
|
Highlights
|
IMD-1041 ameliorated endotoxin-induced uveitis in rats. (Molecular Vision 2012; 18:2586-2597) <http://www.molvis.org/molvis/v18/a268>.
|
|
Alliance strategy
|
We will out-lisense our IMD-1041,0354,2560,4482 compounds.
|
|
|